Biomarin Pharmaceutical Inc BMRN:NASDAQ

Last Price$79.38NASDAQ Previous Close - Last Trade as of 4:00PM ET 9/18/20
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$79.00 (9)
Ask (Size)$79.94 (1)
Day Low / HighN/A - N/A
Volume4.4 M
 

View Biotechnology IndustryPeer Comparison as of 09/18/2020

 

Biomarin Pharmaceutical Inc ( NASDAQ )

Price: $79.38
Change: +1.02 (1.30%)
Volume: 4.4 M
4:00PM ET 9/18/2020
 
 

Alnylam Pharmaceuticals Inc ( NASDAQ )

Price: $132.26
Change: +1.24 (0.95%)
Volume: 1.5 M
3:59PM ET 9/18/2020
 
 

Exact Sciences Corp ( NASDAQ )

Price: $77.47
Change: +2.58 (3.45%)
Volume: 1.8 M
3:59PM ET 9/18/2020
 
 

Sarepta Therapeutics Inc ( NASDAQ )

Price: $144.53
Change: +0.50 (0.35%)
Volume: 1.4 M
3:59PM ET 9/18/2020
 
 

Incyte Corp ( NASDAQ )

Price: $86.79
Change: -3.63 (4.01%)
Volume: 3.3 M
4:00PM ET 9/18/2020
 

Read more news Recent News

BioMarin Pharmaceuticals' 2021 Earnings Forecast Cut
11:20PM ET 9/18/2020 MT Newswires

The December 31, 2021 forecasted earnings estimate for BioMarin Pharmaceuticals (NASDAQ:BMRN, Recent Price: 79.38) has been decreased. This new consensus...

Earnings Forecast for BioMarin Pharmaceuticals in 2021 Reduced
11:25PM ET 9/17/2020 MT Newswires

The December 31, 2021 forecasted earnings estimate for BioMarin Pharmaceuticals (NASDAQ:BMRN, Recent Price: 78.36) has been decreased. This new consensus...

Earnings Forecast for BioMarin Pharmaceuticals in 2021 Cut
11:25PM ET 9/10/2020 MT Newswires

The 2021 forecasted earnings estimate for BioMarin Pharmaceuticals' (NASDAQ:BMRN, Recent Price: 71.87) for the year ending December 31, 2021 has been...

Analyst Actions: Truist Securities Adjusts BioMarin Pharmaceutical PT to $125 From $130, Maintains Buy Rating
1:19PM ET 9/10/2020 MT Newswires

Wall Street price targets on BioMarin Pharmaceutical (BMRN) range from $77 to $218. (MT Newswires covers equity, commodity and economic research from...

Company Profile

Business DescriptionBioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA. View company web site for more details
Address770 Lindaro Street
San Rafael, California 94901
Phone+1.415.506.6700
Number of Employees2,849
Recent SEC Filing09/10/2020SC 13G/A
Chairman & Chief Executive OfficerJean-Jacques Bienaimé
Chief Financial Officer & Executive Vice PresidentBrian R. Mueller
Chief Information OfficerEduardo E. Von Pervieux
President-Worldwide Research & DevelopmentHenry J. Fuchs

Company Highlights

Price Open$78.81
Previous Close$78.36
52 Week Range$62.88 - 131.95
Market Capitalization$14.4 B
Shares Outstanding181.3 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement10/28/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings120.27
Earnings per Share$0.65
Beta vs. S&P 500N/A
Revenue$1.5 B
Net Profit Margin6.72%
Return on Equity3.86%

Analyst Ratings as of 09/17/2020

Buy
14
Overweight
2
Hold
10
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset